JV
Therapeutic Areas
BeOne Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BRUKINSA (zanubrutinib) | B-cell malignancies, CLL/SLL | Approved |
| TEVIMBRA (tislelizumab) | Various solid tumors | Approved |
| BCL2 Inhibitor | B-cell lymphoma | Late-stage |
| CDAC Platform Programs | Multiple oncology indications | Pre-clinical |
| Blood Cancer Portfolio | Chronic Lymphocytic Leukemia | Multiple |
| Lung Cancer Programs | Various lung cancers | Multiple |
| GI Cancer Programs | Gastrointestinal cancers | Multiple |
| Breast/Gynecologic Programs | Breast and gynecologic cancers | Multiple |